Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069264 | 0.88 | EPHX2 (0.52) | HTR2B | |
| Hydrochloric Acid SCHEMBL2067257 | 0.87 | EPHX2 (0.52) | HTR2B | |
| SCHEMBL20204376 | 0.86 | USP30 (0.44) | HTR2BHCRTR1HCRTR2SMN1; SMN2POLB | |
| Trifluoroacetic Acid SCHEMBL2067634 | 0.80 | HTR2B (0.49) | HTR2BSMN1; SMN2 | |
| SCHEMBL9970053 | 0.79 | HTR2B (0.55) | HTR2BSMN1; SMN2 | |
| SCHEMBL9970064 | 0.79 | USP30 (0.41) | HTR2BHCRTR1HCRTR2 | |
| Trifluoroacetic Acid SCHEMBL2067284 | 0.79 | GID4 (0.49) | — | |
| SCHEMBL18536508 | 0.79 | HTR2B (0.41) | HTR2BHCRTR1HCRTR2 | |
| SCHEMBL2067359 | 0.79 | HTR2B (0.41) | HTR2BHCRTR1HCRTR2 | |
| SCHEMBL9970051 | 0.78 | GID4 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | HTR2B 3323/4885MTOR 1627/4885HCRTR1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.